Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A National Multicenter Prospective Cohort Study on the Incidence Characteristics and Risk Associations of Metabolic and Multi-system Comorbidities in Overweight and Obese Populations Stratified by Body Mass Index

NCT07884903 is registered in ClinicalTrials.gov with Shanxi Bethune Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07884903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A National Multicenter Prospective Cohort Study on the Incidence Characteristics and Risk Associations of Metabolic and Multi-system Comorbidities in Overweight and Obese Populations Stratified by Body Mass Index
Lead sponsor
Shanxi Bethune Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
September 30, 2029
Enrollment
25,974 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, diabetes mellitus, type 2, dyslipidemias, hypertension, hyperuricemia, non-alcoholic fatty liver disease (masld), obesity & overweight, polycystic ovary syndrome, sleep apnea, obstructives

Arms

As registered; 4 arms.

  • Overweight No intervention; observational assessment only

    Adults with BMI 23.0-27.4 kg/m². Target enrollment: 7,785 participants.

  • Mild Obesity No intervention; observational assessment only

    Adults with BMI 27.5-32.4 kg/m². Target enrollment: 7,785 participants.

  • Moderate Obesity No intervention; observational assessment only

    Adults with BMI 32.5-37.4 kg/m². Target enrollment: 7,785 participants.

  • Severe Obesity No intervention; observational assessment only

    Adults with BMI ≥37.5 kg/m². Target enrollment: 2,544 participants.

Primary endpoints

Registered primary outcome measures; 4 primary.

  • Incidence of Type 2 Diabetes Mellitus 3 years

    3-year incidence of new-onset type 2 diabetes mellitus diagnosed according to ADA criteria (fasting glucose ≥7.0 mmol/L, HbA1c ≥6.5%, or 2h OGTT ≥11.1 mmol/L)

  • Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 3 years

    3-year incidence of new-onset MASLD diagnosed by abdominal ultrasound and/or FibroScan with hepatic steatosis, excluding other causes of liver disease

  • Incidence of Hypertension 3 years

    3-year incidence of new-onset hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg on at least 2 occasions, or initiation of antihypertensive medication)

  • Incidence of Atherosclerotic Cardiovascular Disease (ASCVD) 3 years

    3-year incidence of ASCVD events including coronary heart disease, cerebral infarction, transient ischemic attack (TIA), and peripheral artery disease, confirmed by clinical diagnosis and imaging

Lead sponsor's other trials

Shanxi Bethune Hospital, most recent start first.

Similar trials

Same condition (Hyperuricemia) and phase, most recent start first.